Skip to main content
. Author manuscript; available in PMC: 2020 Jun 3.
Published in final edited form as: Mol Pharm. 2019 May 14;16(6):2364–2375. doi: 10.1021/acs.molpharmaceut.8b01296

Table 2.

Serum, Antibody Titers (×103) and Cross-Reactivity (%)a

coating immunogen OXY-sKLH 60 μg OXY-sKLH 120 μg M-sKLH 60 μg M-sKLH + OXY-sKLH 60 μg + 60 μg
M-BSA 31 ± 12 (15%) 56 ± 18 (17%) 243 ± 75 164 ± 63
OXY-BSA 213 ± 30b 334 ± 92b 80 ± 26 (33%) 226 ± 71b
a

Cross-reactivity of serum antibodies for the nontargeted hapten was calculated by dividing the antibody titers measured using the nontargeted coating antigen by the antibody titers measured using the targeted coating antigen and multiplying by 100 to obtain a percentage.

b

Compared to the sKLH control group.